Teladoc, Inc. (TDOC) Stock Rating Reaffirmed by KeyCorp
Teladoc, Inc. (NYSE:TDOC)‘s stock had its “buy” rating reaffirmed by equities researchers at KeyCorp in a report issued on Sunday. They presently have a $37.00 price target on the health services provider’s stock. KeyCorp’s price objective suggests a potential upside of 2.92% from the stock’s previous close.
TDOC has been the topic of several other reports. Piper Jaffray Companies reiterated a “buy” rating and set a $42.00 price objective on shares of Teladoc in a research report on Friday, July 28th. Cowen and Company lifted their price objective on shares of Teladoc from $29.00 to $36.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 31st. BidaskClub lowered shares of Teladoc from a “hold” rating to a “sell” rating in a research note on Thursday, August 3rd. Zacks Investment Research lowered shares of Teladoc from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. Finally, Cantor Fitzgerald reissued a “hold” rating on shares of Teladoc in a research note on Monday, August 28th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company. Teladoc presently has a consensus rating of “Buy” and a consensus price target of $35.55.
Shares of Teladoc (TDOC) traded down 2.84% during midday trading on Friday, reaching $35.95. The company’s stock had a trading volume of 1,974,434 shares. The stock’s 50 day moving average is $35.08 and its 200 day moving average is $29.53. Teladoc has a 12 month low of $14.00 and a 12 month high of $37.55. The stock’s market capitalization is $2.04 billion.
Teladoc (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The firm had revenue of $44.60 million for the quarter, compared to analysts’ expectations of $44.39 million. During the same quarter in the previous year, the firm posted ($0.38) earnings per share. The company’s revenue for the quarter was up 68.3% on a year-over-year basis. On average, analysts forecast that Teladoc will post ($1.44) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Teladoc, Inc. (TDOC) Stock Rating Reaffirmed by KeyCorp” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/09/17/teladoc-inc-tdoc-stock-rating-reaffirmed-by-keycorp.html.
In related news, insider Adam C. Vandervoort sold 53,806 shares of Teladoc stock in a transaction on Monday, August 7th. The shares were sold at an average price of $30.92, for a total value of $1,663,681.52. Following the completion of the sale, the insider now owns 33,008 shares of the company’s stock, valued at approximately $1,020,607.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.47% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in TDOC. ETF Managers Group LLC acquired a new stake in shares of Teladoc in the 2nd quarter valued at $104,000. Great West Life Assurance Co. Can acquired a new stake in shares of Teladoc in the 1st quarter valued at $105,000. UBS Asset Management Americas Inc. acquired a new stake in shares of Teladoc in the 1st quarter valued at $106,000. US Bancorp DE lifted its stake in shares of Teladoc by 10.3% in the 1st quarter. US Bancorp DE now owns 4,617 shares of the health services provider’s stock valued at $116,000 after purchasing an additional 433 shares during the last quarter. Finally, Bank of Montreal Can lifted its stake in shares of Teladoc by 214.2% in the 2nd quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock valued at $123,000 after purchasing an additional 2,397 shares during the last quarter.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.